SHERMAN JEFFREY W
SHERMAN JEFFREY W's purchase track record
SHERMAN JEFFREY W has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/27/2026 | LRMR | $25K | -34.5% | -24.7% | +12.1% |
| 11/27/2023 | XERS | $10K | +69.0% | +4.3% | +16.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Xeris Biopharma Highlights Endocrinology Data and Files KEYEVIS Lawsuit. Xeris Biopharma disclosed new data on its commercial portfolio and pipeline at several scientific meetings, emphasizing its role in the endocrinology market. The company also initiated patent infringement lawsuits in New Jersey federal court concerning its KEYEVIS product. These developments provide both scientific validation and legal exposure that may influence market perception.
Transaction History
| LRMR | ▲ Buy | Open Market | 5,000 | $25K | 2/27/2026 | View on chart |
| XERS | ▲ Buy | Option Exercise | 47,040 | $313K | 8/28/2025 | View on chart |
| XERS | ▼ Sell | Open Market | 42,232 | $335K | 8/28/2025 | View on chart |
| XERS | ▲ Buy | Grant | 50,000 | $0 | 6/4/2025 | View on chart |
| XERS | ▲ Buy | Grant | 50,000 | $0 | 6/5/2024 | View on chart |
| XERS | ▼ Sell | Other | 6,502 | — | 3/15/2024 | View on chart |
| XERS | ▲ Buy | Open Market | 5,400 | $10K | 11/27/2023 | View on chart |
| XERS | ▲ Buy | Grant | 42,500 | $0 | 6/7/2023 | View on chart |
| XERS | ▲ Buy | Grant | 15,000 | $0 | 6/8/2022 | View on chart |
| XERS | ▲ Buy | Grant | 50,378 | — | 10/5/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Larimar Therapeutics Names John Harlow as President and COO
Larimar Therapeutics has appointed John Harlow as its new President and Chief Operating Officer, effective September 29. This leadership change is intended to strengthen the company's executive team. The stock is currently trading near its 52-week low, which provides context for this operational update.
Larimar Therapeutics Names John Harlow as President and COO. Larimar Therapeutics has appointed John Harlow as its new President and Chief Operating Officer, effective September 29. This leadership change is intended to strengthen the company's executive team. The stock is currently trading near its 52-week low, which provides context for this operational update.